A comparison of intravenous salbutamol and aminophylline in the management of acute severe asthma in children

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN65396765

Enrollment

Registered

2004-01-23

Start date

2000-01-10

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma Respiratory Asthma

Interventions

1. Bolus of intravenous salbutamol 2. Aminophylline infusion

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age 1 to 15 years 2. Acute severe asthma with an asthma severity score of greater than 7 3. Poor response to 3 "back to back" salbutamol/ipratropium nebulisers with an improvement in asthma severity score of less than 2

Exclusion criteria

Exclusion criteria: 1. A life threatening exacerbation 2. An underlying respiratory disease other than asthma 3. Cardiac disease 4. Treatment with a medication that alters the metabolism of aminophylline

Design outcomes

Primary

Measure	Time frame
Duration of the need for supplementary oxygen to maintain saturations of above 91%.	—

Secondary

Measure	Time frame
Other end points: 1. Asthma severity score two hours after starting intravenous therapy 2. Time to stopping intravenous therapy 3. Time to decision to discharge subject	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026